COMBOGESIC® Non-Opioid Pain Relief Now Accessible to Healthcare Via Mark Cuban Marketplace

COMBOGESIC®: New Hope in Non-Opioid Pain Management

In a significant move for pain management, AFT Pharmaceuticals has introduced COMBOGESIC® (acetaminophen 325 mg/ibuprofen 97.5 mg) to the U.S. market, now available for healthcare organizations via the Mark Cuban Cost Plus Marketplace. This new availability marks a pivotal point in providing essential pain relief without the use of opioids, catering to the ongoing need for non-addictive alternatives in medical settings.

The Significance of COMBOGESIC®

COMBOGESIC® is a prescription-only, fixed-dose combination of two well-established pain relievers: acetaminophen and ibuprofen. This combination is particularly beneficial for adults dealing with mild to moderate acute pain. The product is formulated using AFT's innovative QikSolv® technology, which enhances absorption and efficacy. Thanks to its streamlined purchasing process through the Mark Cuban Cost Plus Marketplace, healthcare providers—including pharmacies, hospitals, and clinics—can now access this medication with ease.

According to recent guidelines from the CDC, non-opioid treatments have been recognized as effective alternatives for managing acute pain, leading to a stronger emphasis in clinical practice on their utilization. Dr. Hartley Atkinson, AFT Pharmaceuticals' founder, emphasizes that COMBOGESIC® is more than just a combination of two familiar medications. Clinical studies reveal that it offers superior pain relief compared to standalone treatments, highlighting its potential to reduce reliance on opioids in acute care settings.

Clinical Evidence and Community Impact

In a Phase 3 study involving 408 participants suffering from pain after dental surgery, only 23.9% of those treated with COMBOGESIC® required additional opioid medication for pain relief, compared to higher rates observed in those exclusively using ibuprofen (43.2%) or acetaminophen (53.2%). Furthermore, COMBOGESIC® demonstrated 78% greater effectiveness than acetaminophen alone and 36% more than ibuprofen alone, with a comparable safety profile to both drugs. These findings underscore the important role of COMBOGESIC® in providing effective, non-opioid pain management.

Mark Cuban, a prominent entrepreneur and founder of the Cost Plus Drug Company, voiced his support for the new partnership with AFT Pharmaceuticals, stating, "We should all get excited to have more prescription non-opioid options to combat pain." The mission behind the Mark Cuban Cost Plus Marketplace is to ensure that all Americans have access to safe and affordable medicines, enhancing overall public health and transcending traditional pharmaceutical pricing concerns.

Navigating the Future of Pain Management

This partnership not only expands the availability of COMBOGESIC® but also aligns with a broader movement to transition away from opioid prescriptions amid the rising opioid crisis. By offering healthcare providers a clinically validated, non-opioid option, AFT Pharmaceuticals is actively contributing to a more responsible medical landscape.

Patients can benefit from this integrated approach in several ways. With a unified dosing regimen eliminating the need to juggle different medications, individuals experiencing acute pain can rely on a single, effective solution prescribed by their healthcare professional.

As COMBOGESIC® enters the U.S. market through this innovative channel, it brings forth a promising alternative for countless patients in need of effective pain management solutions without the accompanying risks associated with opioid medications. With further clinical evidence and expansive educational outreach, AFT Pharmaceuticals aims to solidify COMBOGESIC® as a cornerstone of non-opioid pain management solutions. Healthcare providers eager to enhance patient outcomes can learn more and order COMBOGESIC® online through the Cost Plus Drugs portal.

In conclusion, the introduction of COMBOGESIC® exemplifies a significant stride towards enhancing patient care by addressing the urgent need for alternatives to opioid pain management. As healthcare organizations embrace this new option, the potential ripple effects on public health and patient welfare are substantial, paving the way for a safer future in pain management.